BioSpace News Archive

Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable responses

Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments

Poster presentation highlights Phase 1 clinical trial data demonstrating tolerability, pharmacokinetics and pharmacodynamics of KER-050 in healthy postmenopausal women.

TG Therapeutics, Inc., announced data presentations at the 25th European Hematology Association annual congress including data from a Phase 1 study evaluating TG-1701

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two presentations as part of the 2020 Virtual Cure SMA Research and Clinical Care Meeting.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys® (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Raymond James Human Health Innovation Conference at 3:00 pm ET on Thursday, June 18, 2020. To access a live webcast of the presentation, please visit https://kvgo.com/raymondjames/Catalyst-Biosciences-june-2020 An archived webcast of the p

PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service.

Robust signals of clinical efficacy, with ORR of 77%, of which 60% are CR/CRi Fast clinical responses, with mean time to response of 37 days Longest remission to date 488 days, still ongoing Iadademstat and azacitidine combination shows a good safety profile Results presented at 25th Congress of the European Hematology Association MADRID, Spain and CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinica

RAS Pathway Mutations Were Observed More Commonly in Patients That Progressed on HMA Therapy vs Patients That Failed HMA Therapy Completely